Brief: Asit Biotech Selects New Product Candidate Hdm-Asit+ For Treating House Dust Mite Allergy

European Medical Solutions SA

25/06/2018 07:07

June 25 (Reuters) - ASIT BIOTECH SA  ASIT.BR :
    * ASIT BIOTECH SELECTS A NEW PRODUCT CANDIDATE HDM-ASIT+ FOR
THE
HIGH-POTENTIAL MARKET FOR TREATING HOUSE DUST MITE ALLERGY
    * THIS NEW PRODUCT CANDIDATE HAS BEEN SELECTED TO INDUCE
SAME
MECHANISM OF ACTION AS GP-ASIT+
    * GP-ASIT+ WHICH HAS DEMONSTRATED ITS FAST ONSET OF ACTION
AND ITS
EFFICACY IN AN INITIAL PHASE III TRIAL FOR GRASS POLLEN ALLERGY
    * ASIT BIOTECH NOW HAS THREE PRODUCT CANDIDATES SELECTED ON
ASIT+
PLATFORM FOR ALLERGIES WITH HIGHEST PREVALENCES ALLERGIC
RHINITIS CAUSED BY GRASS POLLEN, PEANUT ALLERGY AND HOUSE DUST
MITE ALLERGY
    * THIS SELECTION WAS INITIATED IN OCTOBER 2017 FOLLOWING
PHASE
I/II FOLLOW-UP STUDY CARRIED OUT WITH FIRST PRODUCT CANDIDATE.

Source text for Eikon:  ID:nBw9MnF3Wa 
Further company coverage:  ASIT.BR 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 09 20;))